ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 61

Epigenome-Wide DNA Methylation Study Reveals Hypermethylated Collagen Genes and Suggests a Role for TGFβ in Osteoarthritis

Matlock A. Jeffries1,2, Amr H. Sawalha3 and Judith A. James4, 1Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Division of Rheumatology, University of Michigan, Ann Arbor, MI, 4Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cartilage, Collagen, epigenetics and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint (Cartilage and Osteoarthritis)

Session Type: Abstract Submissions (ACR)

Background/Purpose: Osteoarthritis (OA) is the leading cause of chronic disability in the U.S., affecting 40% of individuals over the age of 70 and costing $128 billion annually in the US alone.  Late-stage OA chondrocytes exhibit a host of gene transcription changes leading to upregulation of enzymes that contribute to cartilage breakdown. Herein, we characterize epigenome-wide DNA methylation changes in osteoarthritic compared to healthy cartilage from the same joints.

Methods: Twelve femoral heads were obtained at the time of hip arthroplasty for primary OA.  Articular cartilage tissue was dissected from grossly affected and grossly normal areas, flash frozen in liquid nitrogen, and DNA was extracted.  Following sodium bisulfite-treatment, DNA methylation was quantified at >485,000 CpG sites across the genome using Illumina HumanMethylation450 arrays.  CpG sites with an absolute methylation difference between OA and normal cartilage (Db) ≥ 15%, and P <0.01 after correction for multiple testing using a false discovery rate (FDR) of 5%, were considered statistically significant and used for subsequent analysis. 

Results: We found 442 differentially methylated CpG sites in OA compared to normal cartilage from the same joints: 260 hypo- and 182 hypermethylated.  Overrepresented gene sets included “Connective tissue disorder” (n=53, p=4.73E-6 to 7.36E-3), “Developmental disorder” (n=44, p=4.73E-6 to 7.36E-3), and “Skeletal & muscular disorder” (n=59, p=4.73E-6 to 7.36E-3).  Particularly interesting methylation changes in OA include hypermethylation of COL11A2, which functions to maintain spacing and diameter of type II collagen and is mutated in patients with Stickler syndrome and OSMED.  Additional DNA methylation changes detected include hypermethylation of COL6A2, hypomethylation of the fibrillar collagen gene COL1A1, and hypermethylation of COL18A1. Hypermethylation was also noted in multiple CpG sites within the WNT pathway co-receptor LRP5, which is associated with OA in mice and is a genetic susceptibility gene for OA in humans.  Hypomethylation was found at multiple CpG sites in the transcription factor RUNX1.  Upstream regulator analysis identified significant association of TGFβ1 with 44 differentially methylated genes.  Finally, canonical pathway analysis identified enrichment of several pathways, most prominently the ERK signaling pathway among differentially methylated genes (p=1.51E-4).

Conclusion: We detected significant methylation changes in multiple collagen genes in OA. Our data suggest an epigenetic basis for defective collagen production in OA.  Furthermore, we found evidence for epigenetic dysregulation of WNT signaling, and enrichment of genes associated with TGFβ- and ERK-pathway signaling, both of which are enticing targets for OA therapeutics.  This work reinforces a role for genetic/epigenetic interaction in the pathogenesis of OA.


Disclosure:

M. A. Jeffries,
None;

A. H. Sawalha,
None;

J. A. James,

Pfizer Inc,

2,

GSK,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epigenome-wide-dna-methylation-study-reveals-hypermethylated-collagen-genes-and-suggests-a-role-for-tgf%ce%b2-in-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology